Buradasınız

Anasayfa » Content

Assessment of lipid profile changes with respect to severity of liver dysfunction in cirrhosis of liver

Journal Name:

  • Indian Journal of Basic & Applied Medical Research

Publication Year:

  • 2015

Key Words:

Author Name
Abstract (2. Language): 
Objectives: Cirrhosis of Liver is the end stage result of many etiologies affecting Liver. It is important to assess severity since management varies accordingly. Liver plays a central role in lipid metabolism, lipids are known to be altered. Our aim was to assess severity of Cirrhosis by Child Pugh scoring and correlating with Lipid levels. We attempted to know the pattern of lipid abnormalities and assessed its role in prognostication. Methods: This was a Cross sectional study done at Bapuji hospital, a teritary care center at Davangere. 100 cirrhosis patients fulfilling inclusion criteria, were included in the study. Results: Levels of cholesterol, LDL, HDL and VLDL in cases were significantly reduced when compared to control group (P<0.000). Levels of TGL were marginally reduced in cases (P<0.05). Total Cholesterol (P <.001), TGL (P<.02), HDL (P < .05) and LDL (P<.000) showed a significant negative correlation with Severity of Cirrhosis. VLDL had no correlation with the severity of Cirrhosis. Conclusion: From this study, it was found that cholesterol, LDL, HDL and VLDL were significantly lower. The hypolipidemia may be due to decreased synthesis of Apolipoproteins in studies. Reduced HDLc could be attributed to decrease production of LCAT, apoliportien I and II. Hypolipidemia (except VLDL) was correlating to the severity of Cirrhosis. This is comparable to the earlier studies. In conclusion, dyslipidemia exists in patients with cirrhosis. Thus serum Lipid profile may serve as a sensitive indicator of Liver Dysfunction in Cirrhosis.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-assessment-lipid-profile-changes-respect-severity-liver-dysfunction-cirrhosis-liver.pdf
  • 2
56
63
  • English

REFERENCES

References: 

1. Wolf DC. Cirrhosis: http:/emedicine.medscape.com/article/185856-overview. (Accessed
22/10/14)
2. Flint A. Experimental researches into a new excretory function of the liver. Am J Med
Sci1862 ; 44 : 305-65.
3. McIntyre N. et al. Plasma lipids and lipoproteins in liver diseases. Gut 1978 ;19 : 526-30.
4. Phukan JP, Sinha A, Deka JP. Serum lipid profile in alcoholic cirrhosis: A study in a
teaching hospital of north-eastern India. Niger Med J 2013;54:5-9
5. Turley SD, Dietschy JM. Cholesterol metabolism and excretion. In: Arias IM, Jakoby
WB, Popper H, et al., eds. The liver: biology and pathobiology. New York: Raven
Press, 1982:46
6. Clements D, Banerjee S, Smith PM. LCAT activity as a prognostic liver function
test.Lancet. 1990 Sep 22;336 (8717) : 752
7. Poynard T, Bedossa P, Opolon P; Natural history of liver fibrosis progression in patients with
chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet.
1997 Mar 22;349(9055):825-32.
8. Clark JM; The epidemiology of nonalcoholic fatty liver disease in adults. J ClinGastroenterol.
2006 Mar;40(3 Suppl 1):S5-10
9. Phillips GB. The lipid composition of serum in patients with liver disease. J Clinic
Invest 1960 ; 39 : 1639-650.
10. RC, Harry DS, Owen JS et al. Plasma lecithin cholesterol acyl transferase activity and
the lipoprotein abnormalities of parenchymal liver disease. ClinSciMol Med 1978 ; 54 :
36.
11. Habib A, Mihas AA, Abou-AssiSGet al. High-density lipoprotein cholesterol as an
indicator of l iver function and prognosis in noncholestaticcirrhotics.
ClinGastroenterolHepatol. 2005 Mar;3(3): 286-91.
12. Miller JP. Dyslipoproteinaemia of liver disease.BaillieresClinEndocrinolMetab. 1990
Dec;4(4):807-32.
Indian Journal of Basic and Applied Medical Research; March 2015: Vol.-4, Issue- 2, P. 56-63
63
www.ijbamr.com P ISSN: 2250-284X , E ISSN : 2250-2858
13. De Martiis M, Barlattani A, Parenzi A, Sebastiani F. Pattern of lecithin-cholesterol-acyltransferase
(L-CAT) activity in the course of liver cirrhosis. J Int Med Res. 1983;11(4):232-8.
14. Florén CH, Chen CH, Franzén J, Albers JJ. Lecithin: cholesterol acyltransferase in liver
disease.Scand J Clin Lab Invest. 1987 Oct;47(6):613-7
15. Clements D, Banerjee S, Smith PM. LCAT activity as a prognostic liver function
test.Lancet. 1990 Sep 22;336 (8717) : 752.
16. Vergani C, Dioguardi. Serum total lipids, lipoprotein cholesterol and apol ipoprotein A
in infective hepatitis and chronic liver diseases 1978; 14 : 283-89.
17. Spósito et al. Apolipoprotein and lipid abnormalities in chronic liver failure. Brazilian journal
of Medical and Biological Research (1997) 30: 1287-1290
18. Ahaneku JE et al: Abnormal lipid and lipoprotein patterns in liver cirrhosis with and without
hepatocellular carcinoma. J Pak Med Assoc1992, 42(11):260-263
19. D'Arienzo A , Manguso F, Scaglione G, Vicinanza G, Bennato R, Mazzacca G. Prognostic
value of progressive decrease in serum cholesterol in predicting survival in Child-Pugh C viral
cirrhosis. Scand J Gastroenterol. 1998; 33(11):1213-8.
20. Jarikre AE et al. Plasma total cholesterol, high density lipoprotein cholesterol and low density
lipoprotein cholesterol levels in liver cirrhosis in Nigerians. NigQt J Hosp Med 1996;6:157-159
21. Joye S. Varghese, Kolandaivel K, RagulUpadhuyay,Revathy SM, Jayanthi V. Lipoprotein
profile in cirrhosis of liver. European Journal of Gastroenterology &Hepatology 2007, 19:521–
522
22. Perales J , Angel Lasunción M, Cano A, Martín-Scapa MA, Matíes M, Herrera E. Changes in
the lipid profile in chronic hepatopathies. Med Clin (Barc). 1994 Mar 19;102(10):364-8.
23. Breier C, Lisch HJ, BraunsteinerH.. Lipoproteins, HDL-apolipoproteins, activities of hepatic
lipase and lecithin-cholesterol acyltransferase in the plasma of patients with post-alcoholic endstage
liver cirrhosis.KlinWochenschr. 1983 Sep 15;61(18):929-31.
24. Chrostek L, Supronowicz L, Panasiuk A, Cylwik B, Gruszewska E, Flisiak R• Robert
Flisiak.The effect of the severity of liver cirrhosis on the level of lipids and
lipoproteins.ClinExp Med. 2013 Oct 12.
25. FazleSubhan, Imran Khan, RizwanaArif, Abidullah Khan. Serum lipid profile as an indicator of
the severity of liver damage in cirrhotic patients.Rawal Medical Journal: October-December
2012; Vol. 37. No. 4
26. Mandal SK, KoelinaSil, Chatterjee S, Ganguly J, Chatterjee K, PankajSarkar et al. A Study on
Lipid Profiles in Chronic Liver Diseases.Natl J Med Res. 2013; 3(1): 70-72
27. C. Chlouverakis and Peter Harris. Non-esterified fatty acids and lipoprotein lipase activity in
patients with cirrhosis of the liver. Gut, 1961, 2, 233
28. Camps J et al. Plasma lipoprotein alterations in patients with chronic hepatocellular liver
disease resulting from alcohol abuse: effects of alcohol intake cessation. J Hepatol. 1994
Nov;21(5):704-9

Thank you for copying data from http://www.arastirmax.com